GeneDx Announces Indication Expansion To Include Genetic Testing For Cerebral Palsy, Highlighting Focus On Pediatric Rare Disease Patients

GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its industry leading genetic testing to now include cerebral palsy (CP). In conjunction with Cerebral Palsy Awareness Month, the company is expanding its strategy of focusing on pediatric rare disease patients to now include offering testing for pediatric patients with CP. This strategic indication expansion underscores the importance of improving access to exome and genome testing for patients with CP to shorten the diagnostic odyssey and accelerate the path to treatment.

 

GeneDx underscores its commitment to improving patient care by shortening the diagnostic odyssey and accelerating the path to treatment—the most impactful way to support individuals with CP and their families.

 

"More cases of CP may be due to genetic causes than to birth-related injuries6," said Michael Kruer, MD, Director of the Pediatric Movement Disorders Program at Phoenix Children's. "Furthermore, our analyses have shown that more than 1 in 4 genetic forms of CP are clinically actionable7, meaning that detecting a causative gene would be anticipated to change that patient's treatment right now. As gene-targeted therapies continue to grow, that proportion is only expected to increase."